Compare Amer Sports Inc (AS) vs TG Therapeutics Inc (TGTX) Price & Performance

Amer Sports (AS) trades at $33.03, down 8.68% in the past 24 hours, with a bearish technical signal from moving averages. The company reported strong Q1 2026 earnings of $0.38 per share, beating estimates, and raised full-year guidance. Revenue grew 32% year-over-year to $1.95 billion, driven by Arc'teryx and Salomon. Valuation ratios include a P/E of 42.3 and P/S of 2.8. Net income margin stands at 6.5% for 2025.

The outlook is positive due to consistent earnings beats and raised guidance, but high valuation and technical bearishness pose risks. Analyst consensus is strongly bullish with a $58.67 price target, suggesting significant upside. Key risks include reliance on brand momentum and market volatility. Investors should weigh strong fundamentals against current technical weakness.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.